Table 2.

Influence of different factors on isoprenaline‐induced lipolysis in control subjects and RYGB patients at 5‐year follow‐up

	Lipolysis per lipid weight				Lipolysis per fat cell number
	β‐coefficient	SE	p‐value	95% CI	β‐coefficient	SE	p‐value	95% CI
Control or RYGB	−1.6	0.27	<0.0001	−2.2–1.1	−6.0	1.3	<0.00001	−8.5–3.5
Fat cell volume	−3.6	0.53	<0.0001	−4.7–2.6	22.2	2.6	<0.0001	17.2–27.3
Body mass index	−0.001	0.017	0.94	−0.03–0.03	0.12	0.08	0.13	−0.04–0.28
Age	−0.047	0.007	<0.0001	−0.06–0.03	−0.16	0.04	<0.0001	−0.23–0.09
Sex	0.53	0.22	0.014	0.11–0.96	1.5	1.1	0.14	−0.52–3.60
Waist‐to‐hip ratio	−1.74	1.31	0.18	−4.3–0.8	−9.4	6.4	0.14	−21.9–3.1
HOMA	0.066	0.03	0.054	−0.001–0.13	0.34	0.17	0.045	0.008–0.66
Physical activity	−0.13	0.13	0.31	−0.38–0.12	−0.71	0.62	0.25	−1.9–0.51
Type 2 diabetes	−0.23	0.31	0.47	−0.83–0.38	−1.4	1.5	0.34	−4.4–1.5
Hyperlipidemia	−0.19	0.32	0.55	−0.83–0.44	0.63	1.6	0.69	−2.5–3.7
Hypertension	−0.19	0.25	0.45	−0.68–0.30	−1.1	1.2	0.37	−3.4–1.3

Note: A multiple regression model was built for factors known to or that might influence the rate of fat cell lipolysis. Controls are all subjects who had not been subjected to weight reduction surgery at the time of investigation. They were compared with RYGB patients investigated 5 years after surgery.

Note: n = 897 and 896 for lipolysis/lipid weight and/cell, respectively. r² for the model is 0.20 and 0.32 for lipolysis/lipid weight and/cell, respectively.

Abbreviations: CI, confidence interval; HOMA, homeostasis model assessment of insulin sensitivity; RYGB, Roux‐en‐Y gastric bypass; SE, standard error.